ACE and chronic kidney disease: Finally, the use of ACE inhibitors or ARBs was associated with a higher prevalence of CKD in unadjusted models (sHR 2.3; 95% CI: 1.8–3.0), and this association remained significant after adjustment for demographic and clinical factors (adjusted sHR 2.1; 95% CI: 1.6–2.9).